{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:52:54Z","timestamp":1765828374121,"version":"3.40.5"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Aspirin is used for venous thromboembolism (VTE) prophylaxis after total hip and knee arthroplasty (THA\/TKA). However, its efficacy is unclear in patients with multiple VTE risk factors and at risk of aspirin resistance (AR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>To determine the prevalence of risk factors for VTE and AR in patients after THA\/TKA and to determine the relationship between risk factors and drugs prescribed for thromboprophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study of elective\u2010THA\/TKA in six Australian hospitals over a 1\u2010year period. Medical records were manually reviewed to determine demographics, thromboprophylaxis regimen and presence of risk factors. The relationship between individual and cumulative risk factors with the thromboprophylaxis regimen was determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 1011 patients were included with a mean (SD) age of 65.9 (\u00b111.0) years, and 56.4% were female. The five most prevalent risk factors were obesity (59.1%), age \u226565\u2009years (58.2%), hypertension (45.3%), dyslipidaemia (35.9%) and diabetes (19.7%). Most patients had \u22651 risk factor for VTE (93.6%) and AR (93.6%), with 49.0% and 35.0% having \u22653 concurrent VTE and AR risk factors, respectively. The only significant relationship between risk factors and drugs was diabetes (<jats:italic>P<\/jats:italic> &lt;\u20090.01). Rivaroxaban was more commonly used as the number of concurrent VTE risk factors increased (<jats:italic>P<\/jats:italic> &lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients had a high prevalence of VTE and AR risk factors, suggesting aspirin may not be beneficial in many patients. Only diabetes was linked to the selection of thromboprophylaxis. Patients who received rivaroxaban had a greater average number of VTE risk factors. Guidelines should promote individualised prescribing in higher\u2010risk patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.16407","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T09:58:32Z","timestamp":1716371912000},"page":"1275-1282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of risk factors for venous thromboembolism and aspirin resistance in Australian patients undergoing total hip and knee arthroplasty"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9380-2739","authenticated-orcid":false,"given":"Nameer","family":"van Oosterom","sequence":"first","affiliation":[{"name":"School of Pharmacy University of Queensland  Brisbane Queensland Australia"},{"name":"Pharmacy Department Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8105-0090","authenticated-orcid":false,"given":"Michael","family":"Barras","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Queensland  Brisbane Queensland Australia"},{"name":"Pharmacy Department Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-444X","authenticated-orcid":false,"given":"Neil","family":"Cottrell","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000078464.82671.78"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119095606"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2011.09.001"},{"key":"e_1_2_10_5_1","unstructured":"Australian Government.Hospital\u2010Aquired Complication 7 \u2013 Venous Thromboembolism: Australian Commission on Safety and Quality in Health Care; 2018 [Cited 2021 August]. Available from URL:https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/migrated\/SAQ7730_HAC_Factsheet_VenousThromboemolism_LongV2.pdf."},{"key":"e_1_2_10_6_1","unstructured":"Australian Government.Venous Thromboembolism Prevention Clinical Care Standard: Australian Commission on Safety and Quality in Health Care; 2018 [Updated 2018]. Available from URL:https:\/\/www.safetyandquality.gov.au\/wp-content\/uploads\/2018\/10\/D18-34197-VTE_Brochure_FINAL_WEB-VERSION.pdf."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000078469.07362.E6"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"e_1_2_10_9_1","unstructured":"National Institute for Health and Care Excellence (NICE).Venous Thromboembolism in Over 16s: Reducing the Risk of Hospital\u2010Aquired Deep Vein Thrombosis or Pulmonary Embolism; 2018. Available from URL:https:\/\/www.nice.org.uk\/guidance\/ng89."},{"key":"e_1_2_10_10_1","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN).Prevention and Management of Venous Thromboembolism Edinburgh: SIGN; 2010 [Updated 2014] [Cited 2021 August]. Publication no. 122. Available from URL:https:\/\/www.sign.ac.uk\/assets\/sign122.pdf."},{"key":"e_1_2_10_11_1","unstructured":"American Academy of Orthopaedic Surgeons.Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty; 2011Available from URL:https:\/\/www.aaos.org\/uploadedFiles\/PreProduction\/Quality\/Guidelines_and_Reviews\/VTE_full_guideline_10.31.16.pdf."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2404"},{"key":"e_1_2_10_13_1","unstructured":"Queensland Government.Guideline for the Prevention of Venous Thromboembolism (VTE) in Adult Hospitalised Patients. Queensland Health; 2018."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712746"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-11-201306040-00004"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-017-5394-6"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01413-w"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.1942816"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.03.010"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39430.529549.BE"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.19521"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2017-013632"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.15.1593"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.12.010"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000068427"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-20843-5"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-55918-5_1"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029619838066"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1142\/p1010"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12323"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:40:31Z","timestamp":1724028031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/imj.16407"],"URL":"https:\/\/doi.org\/10.1111\/imj.16407","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"type":"print","value":"1444-0903"},{"type":"electronic","value":"1445-5994"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"2023-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}